Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 115-122

  Reardon, David A ^a   Akabani, Gamal ^a   Coleman, R Edward ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Herndon II, James E ^a   McLendon, Roger E ^a   Pegram, Charles N ^a   Provenzale, James M ^a   Quinn, Jennifer A ^a   Rich, Jeremy N ^a   Vredenburgh, James J ^a   Desjardins, Annick ^a   Guruangan, Sri ^a   Badruddoja, Michael ^a   Dowell, Jeanette M ^a   Wong, Terence Z ^a   Zhao, Xiao Guang ^a   Zalutsky, Michael R ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IODINE 131; IRINOTECAN; LOMUSTINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6; TEMOZOLOMIDE; UNCLASSIFIED DRUG; RADIOACTIVE IODINE; TENASCIN;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; APHASIA; ARTICLE; BLOOD TOXICITY; BRAIN CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; DRUG ABSORPTION; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOSARCOMA; HEADACHE; HUMAN; HUMAN TISSUE; MALE; NEUROTOXICITY; NEUTROPENIA; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION NECROSIS; RADIOIMMUNOTHERAPY; RECURRENT CANCER; SALVAGE THERAPY; THROMBOCYTOPENIA; THROMBOSIS; WEAKNESS; WOUND INFECTION; BIOPSY; BRAIN TUMOR; IMMUNOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOPSY; BRAIN NEOPLASMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; TENASCIN;

EID: 33644833474     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.4082     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
3. Gaspar LE, Fisher B, Macdonald DR, et al: Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55-57, 1992
4. Bigner DD, Brown M, Coleman RE, et al: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2: A preliminary report. J Neurooncol 24:109-122, 1995
5. Bigner DD, Brown MT, Friedman AH, et al: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 16:2202-2212, 1998
6. Cokgor I, Akabani G, Kuan CT, et al: Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862-3872, 2000
7. Reardon DA, Akabani G, Coleman RE, et al: Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389-1397, 2002
8. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, et al: Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36:41-55, 1992
9. Zalutsky MR, Moseley RP, Coakham HB, et al: Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49:2807-2813, 1989
10. Bourdon MA, Matthews TJ, Pizzo SV, et al: Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem 28:183-195, 1985
11. Bourdon MA, Wikstrand CJ, Furthmayr H, et al: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43:2796-2805, 1983
12. Bourdon MA, Coleman RE, Blasberg RG, et al: Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res 4:133-140, 1984
13. Colapinto EV, Lee YS, Humphrey PA, et al: The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. Br J Neurosurg 2:179-191, 1988
14. Lee YS, Bullard DE, Wikstrand CJ, et al: Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res 47:1941-1946, 1987
15. Lee YS, Bullard DE, Zalutsky MR, et al: Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res 48:559-566, 1988
16. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-Brain Tumor Treatment Group. Lancet 345:1008-1012, 1995
17. US Food and Drug Administration: Point to consider in the manufacture and testing of monoclonal antibody products for human use. US Food and Drug Administration, 1987
18. Akabani G, Reist CJ, Cokgor I, et al: Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med 40:631-638, 1999
19. Larson DA, Suplica JM, Chang SM, et al: Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol 6:119-126, 2004
20. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
22. Cox D: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
23. Flickinger JC, Loeffler JS, Larson DA: Stereotactic radiosurgery for intracranial malignancies. Oncology 8:81-86, 1994 (discussion 86, 94, 97-98)
24. Gutin PH, Prados MD, Phillips TL, et al: External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21:601-606, 1991
25. Koot RW, Maarouf M, Hulshof MC, et al: Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 88:2796-2802, 2000
26. Laperriere NJ, Leung PM, McKenzie S, et al: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41:1005-1011, 1998
27. Loeffler JS, Alexander E III, Wen PY, et al: Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 82:1918-1921, 1990
28. Masciopinto JE, Levin AB, Mehta MP, et al: Stereotactic radiosurgery for glioblastoma: A final report of 31 patients. J Neurosurg 82:530-535, 1995
29. Scharfen CO, Sneed PK, Wara WM, et al: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24:583-591, 1992
30. Shrieve DC, Alexander E III, Wen PY, et al: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275-284, 1995
31. Sneed PK, Lamborn KR, Larson DA, et al: Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35:37-44, 1996
32. Videtic GM, Gaspar LE, Zamorano L, et al: Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys 45:687-692, 1999
33. Wen PY, Alexander E III, Black PM, et al: Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73:3029-3036, 1994
34. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
35. Reardon DA, Akabani G, Friedman AH, et al: Phase II study of 131-iodine-labeled antitenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors, in Bigner DD (ed): Ninth Annual Meeting of the Society of Neuro-Oncology. Toronto, Ontario, Canada, Duke University Press, 2004, p 381